10 March 2022 | News
XPOVIO, in combination with bortezomib and dexamethasone (XBd), gives patients with relapsed and/or refractory multiple myeloma, a new treatment option
Image credit: shutterstock
Antengene Corporation, a leading innovative commercial stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, announced that the Therapeutic Goods Administration (TGA) of the Australian Government Department of Health has registered XPOVIO (selinexor) for two indications: (1) In combination with bortezomib and dexamethasone (XBd) for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy and (2) in combination with dexamethasone (Xd) for the treatment of adult patients with relapsed and/or refractory multiple myeloma (R/R MM) who have received at least three prior therapies and whose disease is refractory to at least one proteasome inhibitor (PI), at least one immunomodulatory medicinal product (IMiD), and an anti-CD38 monoclonal antibody (mAb).
"The series of approvals granted to XPOVIO in China, South Korea, Singapore and now Australia in the past six months have indicated the drug's enormous therapeutic potential. In Australia, there are around 2,400 diagnosed cases of MM every year, thus presenting an urgent unmet clinical need in the treatment of MM," said Jay Mei, Antengene's Founder, Chairman and CEO. "This approval by the TGA is practice-changing for patients in Australia who have long suffered from MM. We are committed to bringing innovative drugs and therapies to patients with cancer or other life-threatening disease in the Asia Pacific region and around the world. Now, our commercial team is well prepared to further extend patients' access to this novel therapy, building upon our commercialization experience with XPOVIO® launches in China, Singapore and South Korea."